AUG 07, 2018 8:15 AM PDT

Is There a Best Time of Day to Administer Chemo?

WRITTEN BY: Mauri Brueggeman

A recent publication in the Journal of Pharmacological Sciences outlines how the efficacy of L-asparaginase is dose schedule dependent in breast-tumor bearing mice.

Asparagine is an amino acid involved in metabolic control of cell functionality in primarily nerve and brain tissue.  It is a common, non-essential amino acid synthesized by the body from oxaloacetate, which is an intermediate of the citric acid cycle in aerobic glycolysis (ATP producing pathway).  L-asparaginase is an enzyme that enhances the conversion of asparagine which is used by new cells for growth and energy for proliferation.  Without asparagine, DNA and RNA synthesis cease which results in programmed cell death.  Young, undifferentiated lymph cells (lymphoblasts) in particular are dependent on asparagine for energy.   L-asparaginase has been used for nearly a decade in patients with acute lymphoblastic leukemia (ALL) with significant success as a multi-drug chemotherapy treatment.  Researchers have been looking at its use for solid tumors in vitro but have not translated results to in vivo studies for tumor bearing patients. 

A group of Japanese researchers sought to further the understanding of L-asparaginase as a chemotherapy agent for solid tumors through investigation of its mechanism and potential efficacy dependence on changing physiological levels of asparagine in plasma.  In animals, asparagine levels in plasma vary; they are higher in the light phase of a day and much lower in the dark phase of a day. 

They specifically looked at breast-tumor cells and the anti-tumor effects of L-asparaginase in mice while varying the administration schedule to track effect.  The group maintained the mice in standardized light/dark cycle conditions to mimic days and nights.  Tumor cell growth in these mice was significantly inhibited by L-asparaginase when administered during the light cycle hours; conversely, when L-asparaginase was administered in the dark phase, there was no significant anti-tumor activity.  The evidence very clearly suggests differences in anti-tumor therapeutic efficacy of L-asparaginase in these tumorigenic mice based on when doses were given. 

It is not clear if dose schedule is considered for many chemotherapeutic agents in a clinical setting, nor if there is other research showing the value of investigating such concepts.  It is noteworthy to consider if a cancer driving mechanism has any circadian rhythm or regular pattern with potential to affect therapy outcomes.

Sources: Journal of Pharmacological Sciences, NIH PubChem, Polish Archives of Internal Medicine,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
JUN 27, 2021
Cancer
Are e-cigarettes actually helpful for smoking cessation?
JUN 27, 2021
Are e-cigarettes actually helpful for smoking cessation?
New research published in The Lancet Public Health reports on a study that looked at interventions targeting e-cigarette ...
AUG 13, 2021
Drug Discovery & Development
Breast Cancer Drug Reverses Deadly Blood Cancer in Mice
AUG 13, 2021
Breast Cancer Drug Reverses Deadly Blood Cancer in Mice
A drug currently used to treat advanced breast cancers may treat a rare type of leukemia known as myelofibrosis. The stu ...
SEP 02, 2021
Cancer
When Cholesterol Doesn't Kill Cancer, it Makes it Stronger!
SEP 02, 2021
When Cholesterol Doesn't Kill Cancer, it Makes it Stronger!
High cholesterol is associated with an increased risk of several types of cancer, and cancer patients with high choleste ...
OCT 28, 2021
Cancer
NF-κB: a Trick or a Treat for Cancer?
OCT 28, 2021
NF-κB: a Trick or a Treat for Cancer?
A family of proteins, known as transcription factors, regulate the biological process of converting DNA into RNA. T ...
NOV 09, 2021
Microbiology
Can This Cat Parasite Become a Tumor Treatment?
NOV 09, 2021
Can This Cat Parasite Become a Tumor Treatment?
You may have heard of Toxoplasma gondii because it is so common. Cats carry this parasite, and anyone that cleans a litt ...
NOV 15, 2021
Cancer
Dogs Get Cancer Too
NOV 15, 2021
Dogs Get Cancer Too
“Cancer” isn’t a word anyone wants to hear from their doctor. However, many dog owners may not conside ...
Loading Comments...